259 related articles for article (PubMed ID: 20378548)
41. Inter-BRCT linker is probably the most intolerant region of the BRCA1 BRCT domain.
Yadegari F; Farahmand L; Esmaeili R; Zarinfam S; Majidzadeh-A K
J Biomol Struct Dyn; 2024 Jul; 42(11):5734-5746. PubMed ID: 37948190
[TBL] [Abstract][Full Text] [Related]
42. Thermal denaturation of the BRCT tandem repeat region of human tumour suppressor gene product BRCA1.
Pyrpassopoulos S; Ladopoulou A; Vlassi M; Papanikolau Y; Vorgias CE; Yannoukakos D; Nounesis G
Biophys Chem; 2005 Apr; 114(1):1-12. PubMed ID: 15792855
[TBL] [Abstract][Full Text] [Related]
43. Thermal unfolding of human BRCA1 BRCT-domain variants.
Nikolopoulos G; Pyrpassopoulos S; Thanassoulas A; Klimentzou P; Zikos C; Vlassi M; Vorgias CE; Yannoukakos D; Nounesis G
Biochim Biophys Acta; 2007 Jun; 1774(6):772-80. PubMed ID: 17493881
[TBL] [Abstract][Full Text] [Related]
44. Structure-based assessment of BRCA1 and BRCA2 mutations in a small Spanish population.
Salgado J; Zabalegui N; García-Amigot F; Gil MC; González MS; García-Foncillas J
Oncol Rep; 2005 Jul; 14(1):85-8. PubMed ID: 15944772
[TBL] [Abstract][Full Text] [Related]
45. Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations.
Nominé Y; Botuyan MV; Bajzer Z; Owen WG; Caride AJ; Wasielewski E; Mer G
Biochemistry; 2008 Sep; 47(37):9866-79. PubMed ID: 18717574
[TBL] [Abstract][Full Text] [Related]
46. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
Tavtigian SV; Deffenbaugh AM; Yin L; Judkins T; Scholl T; Samollow PB; de Silva D; Zharkikh A; Thomas A
J Med Genet; 2006 Apr; 43(4):295-305. PubMed ID: 16014699
[TBL] [Abstract][Full Text] [Related]
47. Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer.
Kuo WH; Lin PH; Huang AC; Chien YH; Liu TP; Lu YS; Bai LY; Sargeant AM; Lin CH; Cheng AL; Hsieh FJ; Hwu WL; Chang KJ
J Hum Genet; 2012 Feb; 57(2):130-8. PubMed ID: 22277901
[TBL] [Abstract][Full Text] [Related]
48. Identification of a RING protein that can interact in vivo with the BRCA1 gene product.
Wu LC; Wang ZW; Tsan JT; Spillman MA; Phung A; Xu XL; Yang MC; Hwang LY; Bowcock AM; Baer R
Nat Genet; 1996 Dec; 14(4):430-40. PubMed ID: 8944023
[TBL] [Abstract][Full Text] [Related]
49. BRCA1/2 germline missense mutations: a systematic review.
Corso G; Feroce I; Intra M; Toesca A; Magnoni F; Sargenti M; Naninato P; Caldarella P; Pagani G; Vento A; Veronesi P; Bonanni B; Galimberti V
Eur J Cancer Prev; 2018 May; 27(3):279-286. PubMed ID: 28277317
[TBL] [Abstract][Full Text] [Related]
50. Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.
Carvalho M; Pino MA; Karchin R; Beddor J; Godinho-Netto M; Mesquita RD; Rodarte RS; Vaz DC; Monteiro VA; Manoukian S; Colombo M; Ripamonti CB; Rosenquist R; Suthers G; Borg A; Radice P; Grist SA; Monteiro AN; Billack B
Mutat Res; 2009 Jan; 660(1-2):1-11. PubMed ID: 18992264
[TBL] [Abstract][Full Text] [Related]
51. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
52.
Drikos I; Boutou E; Kastritis PL; Vorgias CE
Anticancer Res; 2021 Jun; 41(6):2953-2962. PubMed ID: 34083286
[TBL] [Abstract][Full Text] [Related]
53. BRCA1/2 missense mutations and the value of in-silico analyses.
Sadowski CE; Kohlstedt D; Meisel C; Keller K; Becker K; Mackenroth L; Rump A; Schröck E; Wimberger P; Kast K
Eur J Med Genet; 2017 Nov; 60(11):572-577. PubMed ID: 28807866
[TBL] [Abstract][Full Text] [Related]
54. A new bioinformatics tool to help assess the significance of BRCA1 variants.
Cusin I; Teixeira D; Zahn-Zabal M; Rech de Laval V; Gleizes A; Viassolo V; Chappuis PO; Hutter P; Bairoch A; Gaudet P
Hum Genomics; 2018 Jul; 12(1):36. PubMed ID: 29996917
[TBL] [Abstract][Full Text] [Related]
55. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains.
Magnard C; Bachelier R; Vincent A; Jaquinod M; Kieffer S; Lenoir GM; Venezia ND
Oncogene; 2002 Oct; 21(44):6729-39. PubMed ID: 12360400
[TBL] [Abstract][Full Text] [Related]
56. Low frequency of BRCA1 germline mutations in 45 German breast/ovarian cancer families.
Hamann U; Häner M; Stosiek U; Bastert G; Scott RJ
J Med Genet; 1997 Nov; 34(11):884-8. PubMed ID: 9391879
[TBL] [Abstract][Full Text] [Related]
57. Re-engineering a split-GFP reassembly screen to examine RING-domain interactions between BARD1 and BRCA1 mutants observed in cancer patients.
Sarkar M; Magliery TJ
Mol Biosyst; 2008 Jun; 4(6):599-605. PubMed ID: 18493658
[TBL] [Abstract][Full Text] [Related]
58. Effects on human transcriptome of mutated BRCA1 BRCT domain: a microarray study.
Iofrida C; Melissari E; Mariotti V; Guglielmi C; Guidugli L; Caligo MA; Pellegrini S
BMC Cancer; 2012 May; 12():207. PubMed ID: 22646717
[TBL] [Abstract][Full Text] [Related]
59. Computational and experimental studies of the interaction between phospho-peptides and the C-terminal domain of BRCA1.
Anisimov VM; Ziemys A; Kizhake S; Yuan Z; Natarajan A; Cavasotto CN
J Comput Aided Mol Des; 2011 Nov; 25(11):1071-84. PubMed ID: 22086652
[TBL] [Abstract][Full Text] [Related]
60. Cancer predisposing mutations in BRCT domains.
di Masi A; Gullotta F; Cappadonna V; Leboffe L; Ascenzi P
IUBMB Life; 2011 Jul; 63(7):503-12. PubMed ID: 21698754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
